Update Artikelilmiah: 36168

YUFRI MU`ALIK

NIM

Judul Artikel

Abstrak (Bhs. Indonesia)

Abstrak
COVID-19 merupakan penyakit yang menyerang sistem pernafasan yang disebabkan virus SARS-CoV2. Levofloksasin merupakan salah satu antibiotik yang ditetapkan oleh Kemenkes RI sebagai terapi penanganan COVID-19. Penelitian ini bertujuan untuk mengetahui potensi innteraksi obat levofloksasin pada pasien COVID-19 di RSUD Banyumas. Penelitian ini bersifat deskriptif observasional dengan data rekam medis pasien COVID-19 di RSUD Banyumas periode Juni 2020-Juni 2021 secara total sampling. Analisis interaksi obat menggunakan Lexicomp® Drug Interaction dan Drugs.Interaction Checker. Diperoleh sebanyak 217 sampel dan interaksi obat levofloksasin berpotensi muncul pada 176 pasien (81,11%). Berdasarkan tingkat keparahannya, tingkat mayor sebanyak 106 kejadian (37,06%), tingkat moderate sebanyak 161 kejadian (56,30%) dan tingkat minor sebanyak 19 kejadian (6,64%). Berdasarkan mekanisme kerjanya, interaksi farmakokinetika sebanyak 31 kejadian (10,83%) dan interaksi farmakodinamika sebanyak 255 kejadian (89,17%). Tata laksana yang dapat dilakukan yaitu monitoring ketat khususnya bagi pasien dengan faktor risiko tinggi (lansia, gangguan ginjal, gangguan jantung dan pasien kritis lainnya).

Abtrak (Bhs. Inggris)

COVID-19 is a disease that attacks the respiratory system caused by the SARS-CoV2 virus. Levofloxacin is one of the antibiotics prescribed by the Indonesian Ministry of Health as a treatment for COVID-19. This study aims to determine the potential for levofloxacin drug interactions in COVID-19 patients at the Banyumas Hospital. This research is descriptive observational with medical record data of COVID-19 patients at the Banyumas Hospital for the period June 2020-June 2021 by total sampling. Drug interaction analysis using Lexicomp® Drug Interaction and Drugs.Interaction Checker. A total of 217 samples were obtained and levofloxacin drug interactions had the potential to appear in 176 patients (81.11%). Based on the severity, the major level was 106 events (37.06%), the moderate level was 161 events (56.30%) and the minor level was 19 events (6.64%). Based on the mechanism of action, pharmacokinetic interactions were 31 events (10.83%) and pharmacodynamic interactions were 255 events (89.17%). The management that can be done is close monitoring, especially for patients with high risk factors (elderly, kidney disorders, heart problems and other critical patients).

Kata kunci

Pembimbing 1

Pembimbing 2

Pembimbing 3

Tahun

Jumlah Halaman